NCT06444607 Hereditary Pheochromocytoma Assessment of Tumour Immunologies
| NCT ID | NCT06444607 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Radboud University Medical Center |
| Condition | Pheochromocytoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2029-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-06-01 with a primary completion date of 2029-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the investigators are examining the role of the immune system in pheochromocytoma and paraganglioma. The investigators aim to examine the differences in the immune system between people who have these tumors with and without a hereditary predisposition. The investigators also want to see how the immune system changes during the development of the tumor in people with a hereditary predisposition. Finally, the investigators will compare the data with a control group of people without these tumors. Ultimately, the investigators hope that the results will contribute to the discovery of new immune system-targeted medications for pheochromocytoma and paraganglioma.
Eligibility Criteria
Inclusion Criteria: Part I: * Newly diagnosed patients with PPGL or newly diagnosed patients with (metastatic) PPGL recurrence. * OR patients with mutations which predispose for the development of PPGL. * Aged \> 18 years. Part II: * Confirmed PPGL on pathology. * Aged \> 18 years. Exclusion Criteria: * Unable to provide informed consent. * Active inflammatory or infectious comorbidities. * Other malignancies which are under active treatment (except for basal cell carcinoma, other in situ carcinomas). * Using medication interfering with the immune system * Pregnancy or breastfeeding * A self-reported alcohol consumption of \>21 units per week
Contact & Investigator
Margo Dona, PhD
PRINCIPAL INVESTIGATOR
Radboud University Medical Center
Frequently Asked Questions
Who can join the NCT06444607 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pheochromocytoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06444607 currently recruiting?
Yes, NCT06444607 is actively recruiting participants. Contact the research team at kai.xu@radboudumc.nl for enrollment information.
Where is the NCT06444607 trial being conducted?
This trial is being conducted at Nijmegen, Netherlands.
Who is sponsoring the NCT06444607 clinical trial?
NCT06444607 is sponsored by Radboud University Medical Center. The principal investigator is Margo Dona, PhD at Radboud University Medical Center. The trial plans to enroll 200 participants.